Blockchain Registration Transaction Record

Carmed Pharmaceuticals Celebrates New Peer-Reviewed Study on Vacrol and S-Mix

Carmed Pharmaceuticals announces second peer-reviewed study in 2026 on Vacrol and S-Mix formulations, published in Antioxidants. Learn about the research and U.S. availability.

This news matters because it underscores Carmed Pharmaceuticals' commitment to scientific rigor in an industry often dominated by marketing hype. For consumers, the publication of peer-reviewed research adds credibility to the company's formulations, suggesting that products like Vacrol and S-Mix are backed by legitimate scientific investigation rather than mere anecdotal claims. This could influence purchasing decisions, especially among health-conscious individuals seeking evidence-based wellness solutions. Moreover, the expansion into the U.S. market makes these research-backed formulations more accessible, potentially offering new options for those interested in botanical-based immune and respiratory support. The focus on standardized, quality-controlled formulations also highlights a shift toward transparency and reproducibility in the supplement industry, which may set a new standard for other companies.